2-(4-(4-(4-chlorophenyl)piperazin-1-yl)butyl)benzo[d]thiazole | 1382352-67-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(4-(4-(4-chlorophenyl)piperazin-1-yl)butyl)benzo[d]thiazole
• 英文别名: 2-[4-[4-(4-Chlorophenyl)piperazin-1-yl]butyl]-1,3-benzothiazole
• CAS: 1382352-67-1
• 化学式: C₂₁H₂₄ClN₃S
• 分子量: 385.961
• InChiKey: SCUPEGWTGGLXHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  47.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-(4-(4-chlorophenyl)piperazin-1-yl)butyl)benzo[d]thiazole 在 盐酸 作用下， 以48%的产率得到2-(4-(4-(4-chlorophenyl)piperazin-1-yl)butyl)benzo[d]thiazole dihydrochloride
  参考文献：
  名称：

  Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants

  摘要：

  The synthesis and evaluation of several benzothiazole-based compounds are described in an attempt to identify novel dual-acting 5HT(1A) receptor and SERT inhibitors as new antidepressants. Binding affinities at the 5HT(1A) receptor and the serotonin transporter do not appear to be congruent and other areas of the binding sites would need to be explored in order to improve binding simultaneously at both sites. Compounds 20 and 23 show moderate binding affinity at the 5HT(1A) receptor and the SERT site and thus, have the potential to be further explored as dual-acting agents. In addition, compound 20 binds with low affinity to the dopamine transporter (DAT), the norepinephrine transporter (NET) and 5HT(2C) receptor, which are desirable properties as selectivity for SERT (and not DAT or NET) is associated with an absence of cardiovascular side effects. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2012.03.042
• 作为产物：
  描述：

  5-氯代戊酰氯 在 potassium carbonate 、 potassium iodide 作用下， 以 甲苯 、 乙腈 为溶剂， 生成 2-(4-(4-(4-chlorophenyl)piperazin-1-yl)butyl)benzo[d]thiazole
  参考文献：
  名称：

  Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants

  摘要：

  The synthesis and evaluation of several benzothiazole-based compounds are described in an attempt to identify novel dual-acting 5HT(1A) receptor and SERT inhibitors as new antidepressants. Binding affinities at the 5HT(1A) receptor and the serotonin transporter do not appear to be congruent and other areas of the binding sites would need to be explored in order to improve binding simultaneously at both sites. Compounds 20 and 23 show moderate binding affinity at the 5HT(1A) receptor and the SERT site and thus, have the potential to be further explored as dual-acting agents. In addition, compound 20 binds with low affinity to the dopamine transporter (DAT), the norepinephrine transporter (NET) and 5HT(2C) receptor, which are desirable properties as selectivity for SERT (and not DAT or NET) is associated with an absence of cardiovascular side effects. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2012.03.042

文献信息

• Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants
  作者：Xue Y. Zhu、Jagan R. Etukala、Suresh V.K. Eyunni、Vincent Setola、Bryan L. Roth、Seth Y. Ablordeppey

  DOI：10.1016/j.ejmech.2012.03.042

  日期：2012.7

  The synthesis and evaluation of several benzothiazole-based compounds are described in an attempt to identify novel dual-acting 5HT(1A) receptor and SERT inhibitors as new antidepressants. Binding affinities at the 5HT(1A) receptor and the serotonin transporter do not appear to be congruent and other areas of the binding sites would need to be explored in order to improve binding simultaneously at both sites. Compounds 20 and 23 show moderate binding affinity at the 5HT(1A) receptor and the SERT site and thus, have the potential to be further explored as dual-acting agents. In addition, compound 20 binds with low affinity to the dopamine transporter (DAT), the norepinephrine transporter (NET) and 5HT(2C) receptor, which are desirable properties as selectivity for SERT (and not DAT or NET) is associated with an absence of cardiovascular side effects. Published by Elsevier Masson SAS.